3,5-dicaffeoylquinic acid

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funder: Jingchu University of Technology

Model organisms1

Outcomes

Cellular senescence

downin human cells1

1 study

3,5-dicaffeoylquinic acid decreases cellular senescence in human cells.
“3,5-diCQA remarkably reduced the ROS level and delayed senescence of MRC-5 cells by activating Nrf2.”
CellsMRC-5 cells
3,5-Dicaffeoylquinic Acid Delayed Aging and Promoted Oxidative Stress Tolerance via Activation of the SKN-1/Nrf2 Signaling Pathway
Food science & nutrition17 Feb 2026

Latest

1 in 12 months

Food Science & Nutrition19 Feb